Supplementary Figure S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
Marcelo V. Negrão, Haniel A. Araújo,Giuseppe Lamberti,Alissa J. Cooper,Neal S. Akhave,Teng Zhou,Lukas Delasos,J. Kevin Hicks,Mihaela Aldea,Gabriele Minuti,Jacobi Hines,Jacqueline V. Aredo,Michael Dennis, Turja Chakrabarti,Susan C. Scott,Paolo Bironzo,Matthias Scheffler,Petros Christopoulos,Albrecht Stenzinger,Jonathan W. Riess,So Yeon Kim,Sarah B. Goldberg,Mingjia Li,Qi Wang,Yun Qing,Ying Ni, Minh Truong,Richard Lee,Biagio Ricciuti,Joao Alessi,Jing Wang, Blerina Resuli,Lorenza Landi,Shu-Chi Tseng,Mizuki Nishino,Subba R. Digumarthy,Waree Rinsurongkawong,Vadeerat Rinsurongkawong,Ara A. Vaporciyan,George R. Blumenschein,Jianjun Zhang,Dwight H. Owen,Collin M. Blakely,Giannis Mountzios,Catherine A. Shu,Christine M. Bestvina,Marina Chiara Garassino,Kristen A. Marrone,Jhanelle E. Gray,Sandip Pravin Patel,Amy L. Cummings,Heather A. Wakelee,Jürgen Wolf,Giorgio Vittorio Scagliotti,Federico Cappuzzo,Fabrice Barlési,Pradnya D. Patil, Leylah Drusbosky,Don L. Gibbons,Funda Meric‐Bernstam, John Lee,John V. Heymach,David S. Hong,Rebecca S. Heist,Mark M. Awad,Ferdinandos Skoulidis openalex(2023)
摘要
Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.
更多查看译文
关键词
inhibitor efficacy,comutations
AI 理解论文
溯源树
样例